[go: up one dir, main page]

ECSP13012431A - Combinación del compuesto glyt1 con antipsicóticos - Google Patents

Combinación del compuesto glyt1 con antipsicóticos

Info

Publication number
ECSP13012431A
ECSP13012431A ECSP13012431A ECSP13012431A EC SP13012431 A ECSP13012431 A EC SP13012431A EC SP13012431 A ECSP13012431 A EC SP13012431A EC SP13012431 A ECSP13012431 A EC SP13012431A
Authority
EC
Ecuador
Prior art keywords
glyt1
combination
antipsychotics
compound
schizophrenia
Prior art date
Application number
Other languages
English (en)
Inventor
Jean-Luc Moreau
Joseph G Wettstein
Daniela Alberati
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44512856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012431(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP13012431A publication Critical patent/ECSP13012431A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una combinación farmacéutica de un inhibidor del transportador de glicina (GlyT1) y un fármaco antipsicótico atípico que puede utilizarse para el tratamiento de los síntomas positivos y negativos de la esquizofrenia.
ECSP13012431 2010-08-09 2013-02-07 Combinación del compuesto glyt1 con antipsicóticos ECSP13012431A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10172316 2010-08-09

Publications (1)

Publication Number Publication Date
ECSP13012431A true ECSP13012431A (es) 2013-03-28

Family

ID=44512856

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012431 ECSP13012431A (es) 2010-08-09 2013-02-07 Combinación del compuesto glyt1 con antipsicóticos

Country Status (29)

Country Link
US (1) US20120035156A1 (es)
EP (1) EP2603219B1 (es)
JP (1) JP2013533297A (es)
KR (1) KR101455947B1 (es)
CN (1) CN103068388A (es)
AR (1) AR084401A1 (es)
AU (1) AU2011288536B2 (es)
BR (1) BR112013003068A2 (es)
CA (1) CA2803656A1 (es)
CL (1) CL2013000378A1 (es)
CR (1) CR20130027A (es)
CY (1) CY1115886T1 (es)
DK (1) DK2603219T3 (es)
EA (1) EA201291477A1 (es)
EC (1) ECSP13012431A (es)
ES (1) ES2521596T3 (es)
HR (1) HRP20141199T1 (es)
MA (1) MA34457B1 (es)
MX (1) MX2013001166A (es)
NZ (1) NZ604891A (es)
PE (1) PE20131100A1 (es)
PH (1) PH12013500078A1 (es)
PL (1) PL2603219T3 (es)
PT (1) PT2603219E (es)
SG (1) SG187108A1 (es)
SI (1) SI2603219T1 (es)
TW (1) TW201211019A (es)
WO (1) WO2012019970A1 (es)
ZA (1) ZA201300434B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012304412A1 (en) 2011-09-08 2014-03-27 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
DK3461834T3 (da) 2013-03-13 2021-08-23 Sage Therapeutics Inc Neuroaktive steroider
WO2015082367A1 (en) * 2013-12-03 2015-06-11 F. Hoffmann-La Roche Ag Pharmaceutical composition
IL248567B (en) * 2014-04-30 2022-08-01 Univ Nat Taiwan Use of compounds known as d-amino acid oxidase inhibitors
JP6628745B2 (ja) 2014-06-18 2020-01-15 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびその使用方法
CN112121171A (zh) * 2014-10-07 2020-12-25 萨奇治疗股份有限公司 神经活性化合物及其使用方法
HK1255500A1 (zh) 2015-07-06 2019-08-16 Sage Therapeutics, Inc. 氧固醇及其使用方法
MA54851A (fr) 2015-07-06 2021-12-08 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation
HRP20210526T8 (hr) 2015-07-06 2021-08-20 Sage Therapeutics, Inc. Oksisteroli i postupci za njihovu uporabu
LT3436022T (lt) 2016-04-01 2022-06-27 Sage Therapeutics, Inc. Oksisteroliai ir jų panaudojimo būdai
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MD3481846T2 (ro) 2016-07-07 2021-11-30 Sage Therapeutics Inc 24-Hidroxisteroli 11-substituiți pentru utilizare în tratamentul stărilor legate de NMDA
ES2935057T3 (es) 2016-09-30 2023-03-01 Sage Therapeutics Inc C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA
TWI772331B (zh) 2016-10-18 2022-08-01 美商賽吉醫療公司 氧固醇(oxysterol)及其使用方法
IL297804A (en) 2016-10-18 2022-12-01 Sage Therapeutics Inc Oxysterols and methods of using them
CN107469087A (zh) * 2017-09-10 2017-12-15 孙永丽 用于治疗精神病的制剂
CN117064892A (zh) * 2017-11-14 2023-11-17 爱思开生物制药株式会社 用于预防、减轻、或治疗精神分裂症的包含氨基甲酸酯化合物的共混物
CN121041437A (zh) 2020-01-09 2025-12-02 迪斯克医药公司 用甘氨酸转运蛋白抑制剂治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0413497B8 (pt) 2003-08-11 2021-05-25 Hoffmann La Roche piperazina com ou que substitui grupo fenila, e seu uso e seu processo de preparação, bem como medicamento
WO2006000222A2 (en) * 2004-06-24 2006-01-05 H. Lundbeck A/S The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia
CN101189228A (zh) * 2005-04-08 2008-05-28 辉瑞产品有限公司 用作i型甘氨酸转运抑制剂的二环[3.1.0]杂芳酰胺
GB0612420D0 (en) * 2006-06-22 2006-08-02 Glaxo Group Ltd Compounds
UA94615C2 (uk) * 2006-06-28 2011-05-25 Амген Інк. Інгібітори транспортера-1 гліцину

Also Published As

Publication number Publication date
PL2603219T3 (pl) 2015-03-31
DK2603219T3 (da) 2014-10-13
HRP20141199T1 (hr) 2015-02-13
EP2603219A1 (en) 2013-06-19
ES2521596T3 (es) 2014-11-13
BR112013003068A2 (pt) 2016-06-28
SG187108A1 (en) 2013-02-28
CN103068388A (zh) 2013-04-24
MX2013001166A (es) 2013-03-22
SI2603219T1 (sl) 2014-12-31
KR101455947B1 (ko) 2014-10-28
AU2011288536A1 (en) 2013-01-31
CA2803656A1 (en) 2012-02-16
US20120035156A1 (en) 2012-02-09
KR20130045379A (ko) 2013-05-03
EA201291477A1 (ru) 2013-06-28
AR084401A1 (es) 2013-05-15
CR20130027A (es) 2013-03-04
CL2013000378A1 (es) 2013-05-03
ZA201300434B (en) 2013-09-25
NZ604891A (en) 2015-01-30
PT2603219E (pt) 2014-11-25
CY1115886T1 (el) 2017-01-25
PE20131100A1 (es) 2013-09-23
WO2012019970A1 (en) 2012-02-16
EP2603219B1 (en) 2014-09-17
TW201211019A (en) 2012-03-16
MA34457B1 (fr) 2013-08-01
PH12013500078A1 (en) 2013-03-11
AU2011288536B2 (en) 2014-10-09
JP2013533297A (ja) 2013-08-22

Similar Documents

Publication Publication Date Title
ECSP13012431A (es) Combinación del compuesto glyt1 con antipsicóticos
ECSP14013169A (es) Tableta a prueba de alteración que proporciona liberación inmediata del fármaco
MX2019009853A (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
MX391175B (es) Macrociclos peptidomimeticos.
CU24397B1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b
CY1120646T1 (el) Προγονικα κυτταρα μεσοδερμικης προελευσης
GT201200144A (es) Composición farmacéutica que comprende un agonista de glp-1, una insulina y metionina
MX2013000567A (es) Composiciones farmaceuticas de moduladores de c-met.
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
GT201200230A (es) Inhibidores del virus de la hepatitis c
CR20150250A (es) Nuevos derivados de piridina
ECSP13012414A (es) Combinaciones que comprenden antipsicóticos atípicos y agonistas taar1
EA201590807A1 (ru) Стабильные бесконсервантные мидриатические и противовоспалительные растворы для инъекций
BR112013028512A2 (pt) cápsula
GT201400012A (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
MX2015001553A (es) Composiciones y metodos para reducir el contenido de alcohol en sangre.
CR20150210A (es) Nuevos derivados de pirazina como agonistas receptores de cb2
CL2011000258A1 (es) Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion.
MX2015014757A (es) Derivados de purina como agonistas del receptor de cannabinoides 2 (cb2).
BR112014016803A8 (pt) amidas macrocíclicas como inibidoras de protease
BR112014012521A2 (pt) novos derivados de pirrolidina como inibidores de catepsina
CR20150275A (es) Composición de difenidol de liberación prolongada
CU20150173A7 (es) COMPOSICIÓN FARMACÉUTICA QUE INCLUYE UN INHIBIDOR DE LA HMG-Coa REDUCTASA QUE MINIMIZA LA INTERACCIÓN DEL ÁCIDO ÁCIDO ACETILSALICÍLICO CON LA ESTATINA
SV2015004997A (es) Comprimidos que tienen aceptacion mejorada y buena estabilidad durante el almacenamiento
CL2015000610A1 (es) Derivados de isoxazolidina